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Acute kidney injury (AKI) reflects a broad spectrum of 
clinical presentations ranging from mild to severe injury 
that may result in dysfunction with recovery or nonrecov-
ery, leading to some or permanent and complete loss of 
renal function that is associated with substantial morbid-
ity, mortality and costs. The incidence of AKI is increasing 
because of increased patient’s susceptibility (aging and 
comorbidities) and intensity of exposures (drugs, contrast 
media and major surgery). Despite advancements in diag-
nosis and care practice, AKI remains a disorder usually 
under/late recognized with high mortality [1]. One of the 
hidden reasons for persistent poor clinical outcomes may 
be the delay in timing for nephrology consultation as 
nephrologists are usually involved when severe AKI has 
already settled. According to the “iceberg of AKI” concept, 
many conditions are actually hidden under the cover of the 
tip of the iceberg although they should require the same or 
more attention by nephrologists but are usually unnoticed 
or self-managed by clinicians [2]. The Vicenza ADQI con-
sensus conference group has introduced RIFLE criteria in 
2004, allowing to make a standardized diagnosis of AKI 
and to define its clinical stage [3]. RIFLE classification 
allows characterizing AKI severity based on serum creati-
nine changes and urine output. Different RIFLE classes 
present remarkably different morbidity and mortality 
outcomes. The criteria have been subsequently modified 
leading to the current Kidney Disease Global Outcome Ini-
tiative (KDIGO) guidelines for diagnosis and care of AKI [4, 
5]. Several lines of evidence, however, suggest that current 
diagnostic criteria are inadequate to characterize the con-
tinuum of the AKI syndrome from its initial phases to the 
advanced forms of kidney failure [6]. For this reason, a 
conceptual model of AKI has been developed encompass-
ing all the steps of the syndrome and the relevant clini-
cal consequences [5]. The RIFLE classification has made a 
significant progress [2–4], but it still relies on creatinine, 
precluding the possibility of a timely and accurate AKI 
diagnosis. Creatinine in fact is a poor marker for injury, 
and its elevation may occur 24–48  h after a significant 
insult to the kidney has occurred. Furthermore, its value 
may remain normal in case of subclinical forms of kidney 
dysfunction and damage. Over the last few years, several 
new AKI biomarkers have been discovered and validated 
to improve early detection, differential diagnosis and 
prognosis and better patient management (Figure  1). In 
addition, biomarkers may also be used to identify a status 
of kidney stress or an increased susceptibility to insults. 
In such conditions, they may trigger early preventive and 
protective measures well before AKI becomes manifest 
according to the KDIGO [7]. The utilization of biomarkers 
in AKI has been predicted to mirror what happened in the 
acute coronary syndrome in the absence of ST elevation 
on the electrocardiogram, where cardiac troponin assay 
made possible the diagnosis of non-ST elevation myo-
cardial infarction [8]. However, although some new bio-
markers have been studied and viewed as promising, no 
new biomarker has been universally accepted for routine 
use in clinical practice. Each of new biomarkers presents 
advantages and shortcomings (particularly related to the 
specificity for AKI), and more robust cost-effectiveness 
analyses should be performed before a wide clinical 
adoption. In this issue of the journal, Kashani and col-
leagues publish a very interesting review on biomarkers 
in AKI analyzing the pathway from discovery to clinical 
adoption [9].
The authors reviewed the available literature on char-
acteristics of promising AKI biomarkers that are currently 
the focus of preclinical and clinical investigations. These 
biomarkers include neutrophil gelatinase-associated 
lipocalin, kidney injury molecule 1, liver-type fatty acid-
binding protein, interleukin 18, insulin-like growth factor-
binding protein 7, tissue inhibitor of metalloproteinase 
2, calprotectin, urine angiotensinogen and urine micro-
RNA. The authors describe the clinical performances of 
these biomarkers for diagnosis and prognostication and 
appraise each AKI biomarker’s advantages and limita-
tions as a tool for early AKI recognition and prediction of 
clinical outcomes after AKI.
Some “take-home messages” of this paper should be 
highlighted. First, the roadmap toward a routine adoption 
of biomarkers has to include a thorough health technology 
assessment (HTA) and a well-defined cost-benefit analy-
sis. HTA should consist of a multidisciplinary process that 
provides an appropriate platform for well-designed studies 
and analyses [10]. Second, clinical implementation of AKI 
biomarkers requires a multidisciplinary team approach 
Brought to you by | Universita degli Studi di Padova
Authenticated
Download Date | 2/21/18 11:13 PM
1072      Plebani: Biomarkers of acute kidney injury: a step forward
and a sound alliance among clinical providers and labora-
tory professionals to identify high-risk patients and “pro-
tocolized measurement” of biomarkers. Third, clinical 
prediction models for risk stratification of patients in the 
hospital or Intensive Care Units should be implemented 
via the advent of electronic surveillance tools that are 
able to identify high-risk patients. It was recently empha-
sized that the current biomarker pipeline is “too prone to 
failures” [11]. Improvements can include the use of more 
stringent methodology, better reporting, larger collabo-
rative studies, careful external independent validation, 
rigorous systematic reviews and implementation studies. 
However, the starting point should be a careful considera-
tion of clinical needs. In the case of biomarkers of AKI, 
the clinical needs are evident, but a common weak point 
is the perception of the lack of clinical utility due to little 
availability of effective therapeutic interventions once the 
early diagnosis is established. Current research should 
generate more data by adopting reliable and accurate bio-
markers to identify risk factors and early signs of disease 
to trigger specific interventions potentially affecting the 
patient’s clinical outcomes. By following this roadmap, 
it should be possible to avoid the dramatic failure of the 
biomarker pipeline defined as “lost in translation” [12]. 
Biomarkers may allow to make the diagnosis of subclini-
cal AKI when classic criteria are still within normal range. 
Specific biomarkers may represent a molecular signature 
for a specific type of insult (for example ischemia, sepsis, 
toxic, etc.). Moving from clinical to molecular diagno-
sis of AKI may allow characterizing the causative role of 
specific pathogenic factors and may help to develop indi-
vidual criteria and decision-making frameworks for the 
etiological variants of AKI. In conclusion, the field is in 
continuous evolution, and the curve of adoption seems to 
move forward from early research studies into more struc-
tured clinical utilization. This will require an integrated 
approach where the clinical and the laboratory medicine 
should find a common ground for a new strategic alliance.
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Figure 1: The iceberg of AKI.
Hidden conditions under the cover of the tip of the iceberg when traditional criteria are adopted (A). Improvement in AKI diagnosis by using 
biomarkers (B). From Reference 2, modified.
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